Literature DB >> 28526967

Update on Barriers to Pharmacotherapy for Opioid Use Disorders.

Anjalee Sharma1, Sharon M Kelly1, Shannon Gwin Mitchell1, Jan Gryczynski1, Kevin E O'Grady2, Robert P Schwartz3.   

Abstract

PURPOSE OF REVIEW: The recent heroin and prescription opioid misuse epidemic has led to a sharp increase in the number of opioid overdose deaths in the USA. Notwithstanding the availability of three FDA-approved medications (methadone, buprenorphine, and naltrexone) to treat opioid use disorder, these medications are underutilized. This paper provides an update from the recent peer-reviewed literature on barriers to the use of these medications.
FINDINGS: These barriers are interrelated and can be categorized as financial, regulatory, geographic, attitudinal, and logistic. While financial barriers are common to all three medications, other barriers are medication-specific. The adverse impact of the current opioid epidemic on public health can be reduced by increasing access to effective pharmacotherapy for opioid use disorder.

Entities:  

Keywords:  Barriers to drug abuse treatment; Buprenorphine; Methadone; Naltrexone; Pharmacotherapy for opioid use disorder

Mesh:

Substances:

Year:  2017        PMID: 28526967      PMCID: PMC7075636          DOI: 10.1007/s11920-017-0783-9

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  55 in total

1.  Facilitating entry into drug treatment among injection drug users referred from a needle exchange program: Results from a community-based behavioral intervention trial.

Authors:  Steffanie A Strathdee; Erin P Ricketts; Steven Huettner; Lee Cornelius; David Bishai; Jennifer R Havens; Peter Beilenson; Charles Rapp; Jacqueline J Lloyd; Carl A Latkin
Journal:  Drug Alcohol Depend       Date:  2005-12-20       Impact factor: 4.492

2.  Current and future funding sources for specialty mental health and substance abuse treatment providers.

Authors:  Katharine R Levit; Elizabeth Stranges; Rosanna M Coffey; Cheryl Kassed; Tami L Mark; Jeffrey A Buck; Rita Vandivort-Warren
Journal:  Psychiatr Serv       Date:  2013-06       Impact factor: 3.084

3.  "It takes your heart": the image of methadone maintenance in the addict world and its effect on recruitment into treatment.

Authors:  D E Hunt; D S Lipton; D S Goldsmith; D L Strug; B Spunt
Journal:  Int J Addict       Date:  1985 Nov-Dec

4.  Increases in Drug and Opioid Overdose Deaths--United States, 2000-2014.

Authors:  Rose A Rudd; Noah Aleshire; Jon E Zibbell; R Matthew Gladden
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2016-01-01       Impact factor: 17.586

5.  A randomized controlled trial of interim methadone maintenance.

Authors:  Robert P Schwartz; David A Highfield; Jerome H Jaffe; Joseph V Brady; Carol B Butler; Charles O Rouse; Jason M Callaman; Kevin E O'Grady; Robert J Battjes
Journal:  Arch Gen Psychiatry       Date:  2006-01

6.  Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.

Authors:  Evgeny Krupitsky; Edward V Nunes; Walter Ling; Ari Illeperuma; David R Gastfriend; Bernard L Silverman
Journal:  Lancet       Date:  2011-04-30       Impact factor: 79.321

7.  Incarceration and opioid withdrawal: the experiences of methadone patients and out-of-treatment heroin users.

Authors:  Shannon Gwin Mitchell; Sharon M Kelly; Barry S Brown; Heather Schacht Reisinger; James A Peterson; Adrienne Ruhf; Michael H Agar; Robert P Schwartz
Journal:  J Psychoactive Drugs       Date:  2009-06

8.  Medication assisted treatment in US drug courts: results from a nationwide survey of availability, barriers and attitudes.

Authors:  Harlan Matusow; Samuel L Dickman; Josiah D Rich; Chunki Fong; Dora M Dumont; Carolyn Hardin; Douglas Marlowe; Andrew Rosenblum
Journal:  J Subst Abuse Treat       Date:  2012-12-03

9.  Supply of buprenorphine waivered physicians: the influence of state policies.

Authors:  Bradley D Stein; Adam J Gordon; Andrew W Dick; Rachel M Burns; Rosalie Liccardo Pacula; Carrie M Farmer; Douglas L Leslie; Mark Sorbero
Journal:  J Subst Abuse Treat       Date:  2014-08-02

10.  A call for evidence-based medical treatment of opioid dependence in the United States and Canada.

Authors:  Bohdan Nosyk; M Douglas Anglin; Suzanne Brissette; Thomas Kerr; David C Marsh; Bruce R Schackman; Evan Wood; Julio S G Montaner
Journal:  Health Aff (Millwood)       Date:  2013-08       Impact factor: 6.301

View more
  47 in total

1.  Opioid-related US hospital discharges by type, 1993-2016.

Authors:  Cora Peterson; Likang Xu; Curtis Florence; Karin A Mack
Journal:  J Subst Abuse Treat       Date:  2019-05-10

2.  Comparing Canadian and United States opioid agonist therapy policies.

Authors:  Kelsey C Priest; Lauren Gorfinkel; Jan Klimas; Andrea A Jones; Nadia Fairbairn; Dennis McCarty
Journal:  Int J Drug Policy       Date:  2019-02-11

3.  Commentary on "The More Things Change: Buprenorphine/Naloxone Diversion Continues While Treatment is Inaccessible".

Authors:  Shannon Gwin Mitchell; Jan Gryczynski; Robert P Schwartz
Journal:  J Addict Med       Date:  2018 Nov/Dec       Impact factor: 3.702

4.  Pharmacotherapy, Resource Needs, and Physician Recruitment Practices in Substance Use Disorder Treatment Programs.

Authors:  Hannah K Knudsen; Randy Brown; Nora Jacobson; Julie Horst; Jee-Seon Kim; Elizabeth Collier; Sanford Starr; Lynn M Madden; Eric Haram; Todd Molfenter
Journal:  J Addict Med       Date:  2019 Jan/Feb       Impact factor: 3.702

5.  Evaluating Slow-Release Oral Morphine to Narrow the Treatment Gap for Opioid Use Disorders.

Authors:  M Eugenia Socías; Evan Wood
Journal:  Ann Intern Med       Date:  2017-12-26       Impact factor: 25.391

6.  Young Adults Have Worse Outcomes Than Older Adults: Secondary Analysis of a Medication Trial for Opioid Use Disorder.

Authors:  Marc Fishman; Kevin Wenzel; Jennifer Scodes; Martina Pavlicova; Joshua D Lee; John Rotrosen; Edward Nunes
Journal:  J Adolesc Health       Date:  2020-08-29       Impact factor: 5.012

7.  Emergency department-based peer support for opioid use disorder: Emergent functions and forms.

Authors:  Alan B McGuire; Kristen Gilmore Powell; Peter C Treitler; Karla D Wagner; Krysti P Smith; Nina Cooperman; Lisa Robinson; Jessica Carter; Bradley Ray; Dennis P Watson
Journal:  J Subst Abuse Treat       Date:  2019-06-19

8.  Supporting individuals using medications for opioid use disorder in recovery residences: challenges and opportunities for addressing the opioid epidemic.

Authors:  Jennifer Miles; Jason Howell; Dave Sheridan; George Braucht; Amy Mericle
Journal:  Am J Drug Alcohol Abuse       Date:  2020-02-24       Impact factor: 3.829

9.  Monoclonal Antibodies Counteract Opioid-Induced Behavioral and Toxic Effects in Mice and Rats.

Authors:  Carly Baehr; April Huseby Kelcher; Aaron Khaimraj; Dana E Reed; Sujata G Pandit; David AuCoin; Saadyah Averick; Marco Pravetoni
Journal:  J Pharmacol Exp Ther       Date:  2020-09-26       Impact factor: 4.030

10.  Burden of Mental, Neurological, Substance Use Disorders and Self-Harm in North America: A Comparative Epidemiology of Canada, Mexico, and the United States.

Authors:  Daniel Vigo; Laura Jones; Graham Thornicroft; Rifat Atun
Journal:  Can J Psychiatry       Date:  2019-11-20       Impact factor: 4.356

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.